Ozempic vs. Wegovy
See how Ozempic and Wegovy compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Ozempic and Wegovy contain the same active ingredient, semaglutide, but are approved for different uses: Ozempic treats type 2 diabetes and Wegovy treats chronic weight management.
Wegovy uses a higher maximum dose (2.4 mg) than Ozempic (2 mg), which may explain greater weight loss but also more frequent gastrointestinal side effects during titration.
Using Ozempic for weight loss is off-label, while Wegovy is specifically approved and dosed for that purpose, which affects how insurance handles coverage.
Ozempic vs. Wegovy Drug Summary
Ozempic
Ozempic is a GLP-1 receptor agonist FDA-approved to control blood sugar in adults with type 2 diabetes, alongside diet and exercise. It is also approved to reduce cardiovascular risk in diabetics with heart disease and to slow chronic kidney disease progression. It is given as a once-weekly injection, with the dose increased gradually from 0.25 mg up to a maximum of 2 mg.
Wegovy
Wegovy is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults and adolescents with obesity or overweight plus a weight-related condition. It is also approved to reduce major cardiovascular events in overweight or obese adults with established heart disease. It is given as a once-weekly injection, titrated from 0.25 mg up to a maximum maintenance dose of 2.4 mg.
Ozempic vs. Wegovy Side Effects
Ozempic
Wegovy
Ozempic vs. Wegovy Dosage
Ozempic
Wegovy
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2 mg once weekly | If needed |
| Dose changes | 3 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
Ozempic
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2 mg once weekly | If needed |
| Dose changes | 3 increases | Every 4 weeks |
Wegovy
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
Ozempic vs. Wegovy Indications
Ozempic
Ozempic is approved to help adults with type 2 diabetes manage blood sugar alongside diet and exercise. It also carries approvals to lower cardiovascular risk in diabetics with existing heart disease and to slow progression of chronic kidney disease. It is not FDA-approved for weight loss, though many prescribers use it off-label for that purpose.
Blood sugar control in type 2 diabetes
Cardiovascular risk reduction in diabetics with heart disease
Slows chronic kidney disease progression in diabetics
Off-label: weight loss in people without diabetes
Wegovy
Wegovy is approved for chronic weight management in adults and adolescents 12 and older who have obesity or overweight plus a related health condition. It also carries an approval to reduce major cardiovascular events in overweight or obese adults with established heart disease. It is not approved to treat type 2 diabetes.
Chronic weight management with diet and exercise
Cardiovascular risk reduction in overweight/obese adults with heart disease
Approved for adolescents 12 and older with obesity
Not approved for blood sugar control in diabetes
Ozempic vs. Wegovy Pros and Cons
Ozempic
Ozempic has years of real-world use in type 2 diabetes and carries approvals for cardiovascular and kidney protection that Wegovy does not have. Because it is not approved for weight loss, insurance coverage for that use is inconsistent and any weight-loss use is off-label.
Pros
FDA-approved for type 2 diabetes management
Also reduces cardiovascular risk in diabetics with heart disease
Also slows chronic kidney disease progression
Lower maximum dose may mean fewer GI side effects
Cons
Not FDA-approved for weight loss (off-label use only)
Maximum dose (2 mg) is lower, so less weight loss than Wegovy
Insurance often won't cover it for weight management
Wegovy
Wegovy is the only semaglutide product specifically approved and dosed for weight management, with a higher maintenance dose than Ozempic. That higher dose is linked to more pronounced weight loss but also more frequent gastrointestinal side effects during titration.
Pros
FDA-approved specifically for chronic weight management
Higher maximum dose (2.4 mg) linked to greater weight loss
Also reduces cardiovascular risk in overweight/obese adults with heart disease
Approved for use in adolescents 12 and older
Cons
Not approved to treat type 2 diabetes
Longer titration schedule (16 weeks) before reaching full dose
Higher rates of nausea, diarrhea, and vomiting during titration
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.